Scienture (NASDAQ:SCNX) Coverage Initiated by Analysts at Maxim Group

Maxim Group began coverage on shares of Scienture (NASDAQ:SCNX) in a report released on Tuesday morning,Benzinga reports. The firm issued a buy rating and a $1.50 target price on the stock.

SCNX has been the subject of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Scienture in a research note on Monday, December 29th. Wall Street Zen lowered Scienture from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $1.50.

Scienture Trading Up 3.3%

Shares of NASDAQ SCNX opened at $0.38 on Tuesday. The company has a 50 day simple moving average of $0.49 and a two-hundred day simple moving average of $0.73. The stock has a market cap of $15.62 million, a price-to-earnings ratio of -0.38 and a beta of 3.02. Scienture has a 12 month low of $0.37 and a 12 month high of $3.61.

Hedge Funds Weigh In On Scienture

A hedge fund recently bought a new stake in Scienture stock. Virtu Financial LLC bought a new position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.22% of Scienture at the end of the most recent reporting period. Institutional investors and hedge funds own 5.68% of the company’s stock.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.